Sai Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Sai Life Sciences is poised for a robust growth trajectory, supported by management's commitment to innovation and capacity expansion. Recent commentary from management highlights a significant investment cycle, with planned capital expenditures of ₹1100-1300 Crore aimed at nearly doubling manufacturing capacity by FY27. This strategic move is expected to enhance revenue growth, targeting a CAGR of 15-20% over the next 3-5 years, while maintaining EBITDA margins of 28-30%. However, the company acknowledges potential near-term operational inefficiencies due to these investments. Vista's financial outlook reflects a moderating revenue growth trend, yet the stable margin profile aligns with the company's long-term growth strategy. The competitive landscape remains challenging, with pricing pressures prevalent in the Pharma APIs and CRAMS sector, but the ongoing diversification of supply chains presents opportunities for Sai Life Sciences. Over the next 12-24 months, key opportunities include deepening relationships with large pharma clients and leveraging next-generation technologies. Conversely, watchpoints include the impact of operational inefficiencies and the potential for revenue slowdown amid a steep capex cycle. Overall, the outlook remains cautiously optimistic, with a fair valuation supporting a hold recommendation
Why We Like This Stock
- Management's planned capital expenditures of ₹1100-1300 Crore will nearly double manufacturing capacity, driving future revenue growth
- Targeted revenue CAGR of 15-20% over the next 3-5 years reflects strong long-term fundamentals
- Expansion into next-generation technologies like Peptides and ADCs enhances competitive positioning
Things To Watch Out For
- Near-term operational inefficiencies may temper revenue growth and margin stability
- Pricing pressures in the competitive Pharma APIs and CRAMS sector could impact profitability
- Rich valuations and a steep capex cycle may lead to potential revenue slowdown
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,465 | 1,695 | 2,192 | 2,574 | 2,960 |
| Profit Before Tax (Cr.) | 109 | 230 | 474 | 750 | 807 |
| PBT Margin | 7.4% | 13.6% | 2162.4% | 29.1% | 27.3% |
| Net Profit (Cr.) | 102 | 195 | 384 | 609 | 655 |
| Earnings Per Share | 4.8 | 9.2 | 18.1 | 28.7 | 30.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HDFC Securities | ▲ Buy | 1,280 | 18-May-2026 |
| Jeffries | ▲ Buy | 1,300 | 01-Apr-2026 |
| Kotak Securities | ▲ Buy | 1,225 | 18-May-2026 |
| Moneycontrol | ► Equalweight | nan | 18-May-2026 |
| Morgan Stanley | ▲ Overweight | 1,160 | 08-Apr-2026 |
Company Overview
Show Company Profile
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.